Industry: after 4 + 7, medical representatives will reduce rapidly

[pharmaceutical network market analysis] at present, many industry veterans have said that with the "4 + 7" centralized mining and expansion, the "two ticket system" has been spread out in an all-round way, the water content of drug prices has been gradually squeezed, the pharmaceutical industry is in a profound transformation, the role of pharmaceutical representatives, sales and marketing models are also changing For the winning enterprises, the promotion of medical representatives is no longer needed due to "price for quantity", and the dependence on medical representatives is greatly reduced; for the unsuccessful enterprises, the market itself has been compressed to a very small extent, the number of hospitals that can be visited is reduced, and many medical representatives are no longer needed for promotion It is reported that in the past, many medical representatives could earn hundreds of thousands of dollars a year by virtue of application academic promotion and rebate marketing However, with the promotion of volume purchase and price linkage, there are fewer and fewer drugs with large operating space for medical representatives, and the days of smooth flow are gone forever Guo Xinfeng, partner of Nanjing Leyao Venture Capital Management Co., Ltd., judged that the number of pharmaceutical representatives would decrease rapidly in the future In 2016, there were 3 million medical representatives in China (generally accepted in the industry, without Statistics) Since 2018, especially after 4 + 7, the number of medical representatives will decrease rapidly On the one hand, with the gradual implementation of the volume purchase policy, the clinical role of medical representatives has been significantly weakened At the same time, with the application of Internet technology and other applications, the communication efficiency of doctors has been improved, and doctors have less time to allocate to medical representatives With the popularity of Internet plus medical, smart healthcare, AI medical, online conferencing, remote video and other new modes of promotion, the demand for representatives of medicine, or traditional medicine, will be reduced On the other hand, the industry is changing, and the traditional methods are difficult to adapt to the new situation However, it is not that the industry no longer needs medical representatives, but with the promotion of reform, the traditional means of bringing gold and customer sentiment will be eliminated, and at the same time, new opportunities are emerging He believes that in terms of the current trend of medical reform, higher standards will be put forward for medical representatives in the future On the one hand, financial standardization and academic promotion will require higher education and comprehensive quality of medical representatives At the same time, they must have stable customer relationship and strong business management ability This also means that in the future, the threshold of medical representatives may be further improved, and the professional and comprehensive qualities that medical representatives need to possess will face challenges Some experts pointed out that in addition to the basic salary, accommodation, transportation and other subsidies, the welfare, points and bonus of the project company are important components of the income, including the achievement bonus and growth bonus For the medical representatives who do not change their business, in addition to improving themselves, they also need to look at enterprises and products, especially the growth of enterprises, products and corporate culture In addition, if the pharmaceutical representatives have keen market vision and rich market experience and dare to seek breakthroughs, it is also a good choice to change from "a" to "B" and enter the modern service industry For pharmaceutical enterprises, in the pharmaceutical industry reform, enterprises that first adapt to policy adjustment and pursue profits under compliance will undoubtedly be big winners Liu Wei, general manager of Beijing Jialin pharmaceutical, said innovation is inevitable for enterprises in the face of policy changes He believes that enterprise innovation should not only focus on drug innovation, but also on marketing innovation.